S&P 500   5,069.76 (-0.17%)
DOW   38,949.02 (-0.06%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
S&P 500   5,069.76 (-0.17%)
DOW   38,949.02 (-0.06%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
S&P 500   5,069.76 (-0.17%)
DOW   38,949.02 (-0.06%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
S&P 500   5,069.76 (-0.17%)
DOW   38,949.02 (-0.06%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
NYSE:AMAM

Ambrx Biopharma (AMAM) Stock Price, News & Analysis

$27.94
+0.03 (+0.11%)
(As of 02/28/2024 ET)
Today's Range
$27.90
$27.96
50-Day Range
$13.36
$28.09
52-Week Range
$5.56
$28.15
Volume
3.38 million shs
Average Volume
2.20 million shs
Market Capitalization
$1.76 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.13

Ambrx Biopharma MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
13.6% Downside
$24.13 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.42mentions of Ambrx Biopharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.45) to ($1.28) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.29 out of 5 stars

Medical Sector

909th out of 945 stocks

Biological Products, Except Diagnostic Industry

149th out of 158 stocks


AMAM stock logo

About Ambrx Biopharma Stock (NYSE:AMAM)

Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.

AMAM Stock Price History

AMAM Stock News Headlines

3 Stocks to Buy That Are Up 200% or More in 2024
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Ambrx Biopharma just downgraded at JMP Securities, here's why
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Crude Oil Falls Sharply; Ambrx Biopharma Shares Spike Higher
Why Is Ambrx Biopharma (AMAM) Stock Up 100% Today?
Ambrx Announces Sale to Johnson & Johnson
Ambrix to Join NASDAQ Biotech Index
Ambrx to be Added to the NASDAQ Biotechnology Index (NBI)
Optimistic Outlook on Ambrx Biopharma’s Pipeline Justifies Buy Rating
Goldman Sachs Keeps Their Hold Rating on Ambrx Biopharma (AMAM)
See More Headlines
Receive AMAM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ambrx Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
2/28/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Fax
N/A
Employees
87
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$24.13
High Stock Price Target
$32.00
Low Stock Price Target
$9.00
Potential Upside/Downside
-13.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$7.40 million
Book Value
$3.05 per share

Miscellaneous

Free Float
62,746,000
Market Cap
$1.76 billion
Optionable
Optionable
Beta
-1.88
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Daniel J. O'Connor J.D. (Age 59)
    CEO, President & Director
    Comp: $509.94k
  • Ms. Sonja Nelson CPA (Age 51)
    Chief Financial Officer
    Comp: $1.18M
  • Mr. Andrew P. Aromando (Age 55)
    Chief Operating Officer
  • Dr. Ying J. Buechler Ph.D.
    Chief Technology Officer
  • Dr. Shawn Shao-Hui Zhang Ph.D.
    Chief Scientific Officer & GM of China
  • Mr. Jared Kelly
    Senior VP, General Counsel & Corporate Secretary
  • Mr. Robert Azzara
    Vice President of Human Capital
  • Dr. Sandra Aung Ph.D.
    Chief Clinical Officer
  • Ms. Renu Vaish M.Sc. (Age 57)
    Chief Regulatory Officer














AMAM Stock Analysis - Frequently Asked Questions

Should I buy or sell Ambrx Biopharma stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ambrx Biopharma in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AMAM shares.
View AMAM analyst ratings
or view top-rated stocks.

What is Ambrx Biopharma's stock price target for 2024?

8 Wall Street analysts have issued 12-month price targets for Ambrx Biopharma's shares. Their AMAM share price targets range from $9.00 to $32.00. On average, they predict the company's stock price to reach $24.13 in the next twelve months. This suggests that the stock has a possible downside of 13.6%.
View analysts price targets for AMAM
or view top-rated stocks among Wall Street analysts.

How have AMAM shares performed in 2024?

Ambrx Biopharma's stock was trading at $14.24 at the beginning of 2024. Since then, AMAM stock has increased by 96.1% and is now trading at $27.93.
View the best growth stocks for 2024 here
.

When is Ambrx Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our AMAM earnings forecast
.

What ETFs hold Ambrx Biopharma's stock?

ETFs with the largest weight of Ambrx Biopharma (NYSE:AMAM) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

When did Ambrx Biopharma IPO?

(AMAM) raised $126 million in an initial public offering on Friday, June 18th 2021. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs, BofA Securities and Cowen served as the underwriters for the IPO.

Who are Ambrx Biopharma's major shareholders?

Ambrx Biopharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Nextech Invest Ltd. (4.96%), Balyasny Asset Management L.P. (3.41%), Vanguard Group Inc. (2.22%), Price T Rowe Associates Inc. MD (1.72%), Price T Rowe Associates Inc. MD (1.72%) and WuXi AppTec Co. Ltd. (1.58%). Insiders that own company stock include Cormorant Asset Management, Lp, Daniel J O'connor and Sonja Nelson.
View institutional ownership trends
.

How do I buy shares of Ambrx Biopharma?

Shares of AMAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:AMAM) was last updated on 2/28/2024 by MarketBeat.com Staff